<DOC>
	<DOCNO>NCT00006025</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness temozolomide plus irinotecan treating patient recurrent malignant glioma .</brief_summary>
	<brief_title>Temozolomide Plus Irinotecan Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity irinotecan administer temozolomide patient recurrent malignant glioma . - Determine safety profile regimen patient population . - Determine efficacy treatment regimen measure 6-month progression-free survival objective tumor response patient . - Characterize pharmacokinetics treatment regimen patient . - Determine antitumor activity treatment regimen patient . OUTLINE : This multicenter , dose-escalation study irinotecan . Patients stratify accord concurrent enzyme-inducing anti-epileptic drug ( EIAEDs ) ( e.g. , phenytoin , phenobarbital , carbamazepine , primidone ) ( yes v ) . In phase I study , patient receive oral temozolomide day 1-5 irinotecan IV 90 minute day 1 14 . Treatment continue every 28 day 1 year absence disease progression unacceptable toxicity . Patients concurrently EIAEDs undergo dose escalation irinotecan . Cohorts 3 6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . In phase II study , patient receive treatment phase I MTD . Patients follow every 2 month 1 year , every 3 month 1 year , every 4 month 1 year , every 6 month progression , every 4 month survival . PROJECTED ACCRUAL : A total 30 patient accrued phase I within 10 month 48 patient accrue phase II within 6-8 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial malignant primary glioma one follow subtypes : Glioblastoma multiforme Anaplastic astrocytoma Anaplastic oligodendroglioma Mixed malignant glioma Original histology lowgrade glioma allow subsequent histological confirmation malignant glioma Measurable recurrent residual primary disease MRI Lesions clearly define margin Evidence tumor recurrence progression MRI CT scan Confirmation true progressive disease PET thallium scan , magnetic resonance spectroscopy , surgical documentation prior interstitial brachytherapy stereotactic radiosurgery No 3 relapse prior chemotherapy/cytotoxic therapy ( include polifeprosan 20 carmustine implant ) phase I 2 relapse phase II PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No uncontrolled hypertension , unstable angina , symptomatic congestive heart failure No myocardial infarction within past 6 month No serious uncontrolled cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No mental incapacitation HIV negative No AIDSrelated disease No significant ongoing alcoholism substance abuse No severe nonmalignant systemic disease No active infection No severe disease would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior interferon thalidomide recover No concurrent anticancer immunotherapy No concurrent sargramostim ( GMCSF ) No concurrent prophylactic filgrastim ( GCSF ) first course study therapy Chemotherapy : See Disease Characteristics Recovered prior chemotherapy At least 2 week since prior vincristine At least 3 week since prior procarbazine At least 4 week since prior cytotoxic chemotherapy ( 6 week nitrosourea ) Prior radiosensitizers allow No prior temozolomide irinotecan No concurrent anticancer chemotherapy Endocrine therapy : At least 1 week since prior tamoxifen recover No concurrent anticancer hormonal therapy Phase II : Nonincreasing dose corticosteroid allow Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent anticancer radiotherapy Surgery : See Disease Characteristics At least 13 week since prior surgical resection recover Other : At least 1 week since prior noncytotoxic agent ( e.g. , isotretinoin ) recover Concurrent enzymeinducing antiepileptic drug without steroid allow No concurrent valproic acid single agent No concurrent medication would preclude study ( e.g. , nonsteroidal immunosuppressive agent ) No concurrent investigational drug No concurrent participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>